Abiel srl (Biomedical and Industrial Applications of Lytic Enzymes) is a new biotechnology company founded in 2010 as a a spin-off of Palermo University and CNR. The company’s is committed to R&D, production and marketing of innovative and high quality lytic enzymes mainly utilized in the field of tissue dissociation for cell therapy and TERM treatments. Abiel aims to become an international leader in the discovery, development and marketing of innovative and value-added lytic enzymes for TERM, biopharmaceutical and industrial applications. The Company currently produces by synthesis two patented collagenases (G- class I and H- class II ) using recombinant DNA techniques. These innovative enzymes are well standardized and characterized by a higher stability, and by a lack of toxic contaminants. Abiel is strongly pursuing the following R&D activities to implement its growth and sustainable programs:
- To characterize and purify proteolytic enzymes from marine organisms, able to work at low temperatures (<20°C) therefore preserving the structural and functional characteristics in the processes where they are applied.
- To generate other recombinant enzymes, obtained using particular techniques of molecular biology able to produce such enzymes in a high quantity and pure fractions.
Abiel also provides several services in the field of lityc enzymes, particularly the screening, characterization and production of lytic enzymes from biomarine and other natural resources. |
